Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Core Viewpoint - Aptorum Group Limited has entered into a securities purchase agreement to sell 1,535,000 Class A Ordinary Shares at an offering price of $2.00 per share, aiming to raise approximately $3.0 million in gross proceeds [1][2]. Group 1: Offering Details - The registered direct offering is expected to close on or about January 3, 2025, pending customary closing conditions [2]. - Maxim Group LLC is acting as the sole placement agent for this offering [3]. - The offering is conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on January 19, 2023 [3]. Group 2: Company Overview - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on developing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [5]. - The company is also involved in the co-development of Paths Test, a rapid pathogen identification and detection technology, in collaboration with Accelerate Technologies Pte Ltd [5].